- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Revance The is a biotechnology business based in the US. Revance The shares (RVNC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.07 – a decrease of 0.32% over the previous week. Revance The employs 597 staff and has a trailing 12-month revenue of around $256.9 million.
Our top picks for where to buy Revance The stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Revance The stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – RVNC. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Revance The stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Revance The stock price (NASDAQ: RVNC)
Use our graph to track the performance of RVNC stocks over time.Revance The shares at a glance
Information last updated 2024-12-18.
| Latest market close | $3.07 |
|---|---|
| 52-week range | $2.30 - $9.75 |
| 50-day moving average | $4.50 |
| 200-day moving average | $4.41 |
| Wall St. target price | $8.21 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.34 |
Is it a good time to buy Revance The stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revance The price performance over time
Historical closes compared with the close of $3.07 from 2024-12-18
| 1 week (2024-12-13) | -0.32% |
|---|---|
| 1 month (2024-11-21) | -20.05% |
| 3 months (2024-09-20) | -47.16% |
| 6 months (2024-06-20) | 6.97% |
| 1 year (2023-12-20) | -59.50% |
|---|---|
| 2 years (2022-12-20) | -84.30% |
| 3 years (2021-12-20) | 16.71 |
| 5 years (2019-12-20) | 16.23 |
Revance The financials
| Revenue TTM | $256.9 million |
|---|---|
| Gross profit TTM | $-20,388,000 |
| Return on assets TTM | -24.36% |
| Return on equity TTM | -2096.78% |
| Profit margin | -71.78% |
| Book value | $-1.55 |
| Market Capitalization | $320.5 million |
TTM: trailing 12 months
Revance The share dividends
We're not expecting Revance The to pay a dividend over the next 12 months.
Revance The share price volatility
Over the last 12 months, Revance The's shares have ranged in value from as little as $2.3 up to $9.745. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Revance The's is 0.953. This would suggest that Revance The's shares are less volatile than average (for this exchange).
Revance The overview
Revance Therapeutics, Inc. , a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA.
Frequently asked questions
What percentage of Revance The is owned by insiders or institutions?Currently 8.557% of Revance The shares are held by insiders and 82.894% by institutions. How many people work for Revance The?
Latest data suggests 597 work at Revance The. When does the fiscal year end for Revance The?
Revance The's fiscal year ends in December. Where is Revance The based?
Revance The's address is: 1222 Demonbreun Street, Nashville, TN, United States, 37203 What is Revance The's ISIN number?
Revance The's international securities identification number is: US7613301099 What is Revance The's CUSIP number?
Revance The's Committee on Uniform Securities Identification Procedures number is: 761330109
More resources on Finder
More guides on Finder
-
How to buy Merck-and-Company stock (MRK)
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
-
How to buy Eli Lilly and Company stock (LLY)
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
-
How to buy Intuitive Surgical stock (ISRG)
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
-
How to buy Vertex Pharmaceuticals stock (VRTX)
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
-
How to buy McKesson Corporation stock (MCK)
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
-
How to buy UnitedHealth Group Incorporated stock (UNH)
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
-
How to buy Amgen stock (AMGN)
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
-
How to buy Abbott Laboratories stock (ABT)
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
-
How to buy Pfizer stock (PFE)
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
-
How to buy Johnson & Johnson stock (JNJ)
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.
Ask a question